Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March

15 Apr 2026, 19:56 by Teresa Graham · The Cerbat Gem

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 6,053,456 shares, a decrease of 26.3% from the March 15th total of 8,215,500 shares. Based on an average daily trading volume, of 2,117,376 shares, the days-to-cover ratio is presently 2.9 days. Approximately 13.7% of the shares of the company are short sold.

Insider Activity at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,230 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the completion of the transaction, the director owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $1,508,580. This trade represents a 16.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 37,460 shares of company stock worth $1,041,104 in the last three months. 25.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after acquiring an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after purchasing an additional 80,506 shares in the last quarter. Jane Street Group LLC acquired a new stake in Enliven Therapeutics during the 1st quarter worth about $578,000. Legal & General Group Plc lifted its stake in Enliven Therapeutics by 52.2% during the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after buying an additional 11,058 shares in the last quarter. Finally, Quantbot Technologies LP boosted its holdings in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Down 2.0%

Enliven Therapeutics stock traded down $0.90 during midday trading on Wednesday, hitting $43.95. The company’s stock had a trading volume of 865,775 shares, compared to its average volume of 1,309,876. The stock’s 50-day moving average price is $32.42 and its 200-day moving average price is $25.01. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $46.31. The company has a market capitalization of $2.63 billion, a PE ratio of -23.63 and a beta of 0.26.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). As a group, equities analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ELVN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Mizuho boosted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Wall Street Zen lowered shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, HC Wainwright boosted their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.40.

Get Our Latest Stock Analysis on Enliven Therapeutics

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.